Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS) is a publicly traded, clinical-stage oncology company that focuses on the development and commercialization of small molecule therapeutics. The company primarily targets rare tumors and aggressive cancers through its innovative treatments. Ayala's leading candidate, AL102, is an investigational small molecule gamma secretase inhibitor currently in the Phase 3 RINGSIDE study for the treatment of desmoid tumors. The promising data from Phase 2 shows significant anti-tumor activity and high overall response rates.
Ayala's strategic vision was further enhanced by its merger with Biosight Ltd., which brought aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML), into its portfolio. AL102 has received FDA Fast Track and Orphan Drug Designations for the treatment of desmoid tumors, highlighting its potential impact in oncology.
Recently, Ayala entered into a definitive asset purchase agreement with Immunome, Inc. to sell AL102 and related drug candidate AL101. This agreement, valued at over $50 million, will allow Immunome to advance AL102 through clinical trials and towards potential commercialization. The transaction is expected to be completed by the end of Q3 2024, pending regulatory approvals.
Ayala is committed to advancing its remaining pipeline, which includes aspacytarabine (BST-236) for AML. Despite the sale of its key assets, Ayala continues to focus on developing impactful treatments within oncology, leveraging its expertise and the clinical data it has gathered.
For more information, please visit www.ayalapharma.com.
Advaxis, Inc. (Nasdaq: ADXS) has announced a public offering of 26,666,666 shares of common stock and warrants to purchase 13,333,333 shares at $0.30 per unit. The warrants are exercisable at $0.35 each and will expire in five years. The underwriters have a 30-day option to purchase additional shares to cover over-allotments. Proceeds will support R&D initiatives, including the ADXS-HOT program, and may also fund acquisitions of new businesses or technologies. A.G.P./Alliance Global Partners is the book-running manager for this offering.
Advaxis, Inc. (Nasdaq: ADXS) has announced plans for an underwritten public offering of its common stock and warrants to purchase common stock. The company intends to grant underwriters a 30-day option to purchase an additional 15% of the offered shares. Proceeds will support research and development efforts, particularly the ADXS-HOT program, and potential investments in other businesses or technologies. The offering is subject to market conditions, and further details will be provided in a prospectus supplement.
Advaxis, Inc. (Nasdaq: ADXS) reported promising results from its Phase 1/2 study of ADXS-503 in combination with KEYTRUDA® for non-small cell lung cancer (NSCLC). The study showed a disease control rate of 67% and an overall response rate of 17% in six evaluable patients who had progressed on KEYTRUDA®. ADXS-503 was safe and well-tolerated, suggesting it may enhance response to checkpoint inhibitors. Data presented highlighted the activation of immune responses, with four patients showing durable benefits from the combination therapy, with two treated for over ten months.
Advaxis, Inc. (ADXS) announced promising results from its Phase 1/2 study of ADXS-503 combined with KEYTRUDA in non-small cell lung cancer (NSCLC). The study reported a 67% disease control rate in six patients who had progressed on KEYTRUDA, significantly higher than the 45% control rate in similar studies. Notable durability was observed, with two patients maintaining tumor control for over 43 weeks. The ongoing trial aims to confirm safety and efficacy as it progresses through its expansion phases.
Advaxis, Inc. (Nasdaq: ADXS) announced its participation at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020), presenting an ePoster on November 12th and 14th. The presentation will focus on a Phase 1/2 study of ADXS-503, a multi-neoantigen vector, alone and with Pembrolizumab in metastatic non-small cell lung cancer (NSCLC). This innovative immunotherapy product utilizes bioengineered Listeria monocytogenes to stimulate anti-tumor T cell immunity. For more details, the poster will be accessible on Advaxis' website.
Advaxis, Inc. (Nasdaq: ADXS) announces the FDA's approval of a new Investigational New Drug (IND) application for an Investigator Sponsored Phase 1 study of ADXS-504 in prostate cancer. This follows the earlier Advaxis IND announced in January 2020. The study is slated to begin in Q4 2020, focusing on patients with biochemical recurrence. The strategic transition aims to leverage academic expertise, enhance patient enrollment, and conserve resources for Advaxis's broader neoantigen program, particularly in non-small cell lung cancer (NSCLC).
Advaxis, Inc. (Nasdaq: ADXS) announced that Chief Financial Officer Molly Henderson resigned effective September 25, 2020, to pursue another opportunity. Kenneth A. Berlin, the President and CEO, will take on the CFO role on an interim basis until a replacement is appointed. Berlin expressed gratitude for Henderson's contributions over the past two years, highlighting her leadership and financial management that advanced the company's immunotherapy programs.
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company, announced that its CEO, Kenneth A. Berlin, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. Berlin's presentation is scheduled for Wednesday, September 2, at 3:40 PM ET. Advaxis focuses on developing proprietary Lm-based immunotherapy products using bioengineered Listeria monocytogenes to stimulate anti-tumor T cell immunity. For more details, interested parties can access the webcast via a provided link.
Advaxis, Inc. (ADXS) has announced an expansion of its Phase 1/2 study of ADXS-503 in non-small cell lung cancer (NSCLC) after observing sustained clinical responses in two patients previously treated with KEYTRUDA®. The company is increasing enrollment in Part B and initiating Part C to evaluate ADXS-503 as a first-line regimen for patients ineligible for standard platinum-based chemotherapy. Financial results for Q2 2020 show R&D expenses dropped to $3.9 million from $6.0 million YoY, with $28.2 million in cash on hand, sufficient for operations until at least August 2021.
Advaxis, a clinical-stage biotechnology company (Nasdaq: ADXS), will announce its financial results for the second quarter ending April 30, 2020, on June 11, 2020. A conference call is scheduled for 11:00 AM EDT that same day, providing a business update. Advaxis specializes in developing immunotherapy products based on a unique platform utilizing live attenuated Listeria monocytogenes to enhance anti-tumor T cell immunity.
FAQ
What is the current stock price of Ayala Pharm (ADXS)?
What is the market cap of Ayala Pharm (ADXS)?
What is the primary focus of Ayala Pharmaceuticals?
What are Ayala’s leading candidates under development?
What significant recent transaction has Ayala Pharmaceuticals entered into?
What is AL102 and what phase is it currently in?
What are the FDA designations achieved by AL102?
What was the result of Ayala's merger with Biosight Ltd.?
What is aspacytarabine (BST-236) used for?
What recent clinical milestone has Ayala achieved?
What is the significance of the sale of AL102 to Immunome?
What will Ayala focus on after the sale of AL102?
